Cipla — While COVID scope continues, watch out for FY23

Trading Calls - Equity F&O

Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic

Anubhav Sahu